A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

This study is a multicenter, open-label study of polatuzumab vedotin administere d by intravenous (IV) infusion in combination with standard doses of bendamustin e (B) and rituximab (R) or obinutuzumab (G) in patients with relapsed or refract ory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase 1b dose-escalation stage and a Phase 2 stage. The anticipated time on treatment is 18-24 weeks.